More recently, Margetuximab (Margenza ®) has been approved by the FDA based on data from a SOPHIA trial that demonstrated the major advantage of Margetuximab compared with TZ in combination with chemotherapy in pre-treated HER-2+ metastatic BC patients [33]. This evidence concerns the gene ERBB2 and breast cancer.